NASDAQ:RLYB Rallybio (RLYB) Stock Price, News & Analysis $1.10 -0.01 (-0.90%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.10▼$1.1550-Day Range$1.09▼$1.4552-Week Range$1.09▼$5.96Volume107,166 shsAverage Volume714,479 shsMarket Capitalization$45.59 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Rallybio alerts: Email Address Rallybio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside809.1% Upside$10.00 Price TargetShort InterestHealthy3.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.45) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 starsMedical Sector410th out of 910 stocksPharmaceutical Preparations Industry183rd out of 426 stocks 3.3 Analyst's Opinion Consensus RatingRallybio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageRallybio has only been the subject of 2 research reports in the past 90 days.Read more about Rallybio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.11% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rallybio has recently increased by 6.46%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRallybio does not currently pay a dividend.Dividend GrowthRallybio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RLYB. Previous Next 2.4 News and Social Media Coverage News SentimentRallybio has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Rallybio this week, compared to 1 article on an average week.Search Interest1 people have searched for RLYB on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Rallybio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rallybio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.40% of the stock of Rallybio is held by insiders.Percentage Held by Institutions90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rallybio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Rallybio are expected to grow in the coming year, from ($1.45) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rallybio is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rallybio is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRallybio has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Rallybio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Rallybio Stock (NASDAQ:RLYB)Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.Read More RLYB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLYB Stock News HeadlinesSeptember 5 at 2:45 AM | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Rallybio (NASDAQ:RLYB)September 4 at 5:06 AM | markets.businessinsider.comBuy Rating on Rallybio Stock Fueled by Promising RLYB212 Trial Outcomes and Potential FNAIT Treatment BreakthroughSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 30, 2024 | markets.businessinsider.comBuy Rating on Rallybio: Promising RLYB212 Developments Signal Strong Market PotentialAugust 29, 2024 | finance.yahoo.comRallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and HaemostasisAugust 28, 2024 | americanbankingnews.comBrokerages Set Rallybio Co. (NASDAQ:RLYB) Price Target at $10.00August 28, 2024 | americanbankingnews.comRallybio (NASDAQ:RLYB) Rating Reiterated by Evercore ISIAugust 27, 2024 | businesswire.comNational Vision Releases 2023 Sustainability ReportSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 27, 2024 | businesswire.comRallybio to Present at Upcoming Investor ConferencesAugust 10, 2024 | ca.finance.yahoo.comRallybio Corporation (RLYB) Stock Historical Prices & Data - Yahoo FinanceAugust 10, 2024 | finance.yahoo.comIs Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?August 9, 2024 | markets.businessinsider.comRLYB Stock Earnings: Rallybio Misses EPS for Q2 2024August 9, 2024 | markets.businessinsider.comRallybio’s RLYB212 Shows Promise: Buy Rating Affirmed Amid Positive Trial and Market PotentialAugust 8, 2024 | 247wallst.com4 Stocks Under $5 To Buy NowAugust 8, 2024 | stockhouse.comRallybio Reports Second Quarter 2024 Financial Results and Provides Business UpdatesJune 17, 2024 | businesswire.comRallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse PopulationsMay 31, 2024 | investorplace.com3 Sorry Biotech Stocks to Sell in May While You Still CanSee More Headlines Receive RLYB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLYB CUSIPN/A CIK1739410 Webwww.rallybio.com Phone203-59-3820FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$15.00 Low Stock Price Target$6.00 Potential Upside/Downside+809.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,560,000.00 Net MarginsN/A Pretax Margin-23,895.65% Return on Equity-74.08% Return on Assets-67.07% Debt Debt-to-Equity RatioN/A Current Ratio7.52 Quick Ratio7.52 Sales & Book Value Annual Sales$299,000.00 Price / Sales152.49 Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.39Miscellaneous Outstanding Shares41,449,000Free Float38,382,000Market Cap$45.59 million OptionableNot Optionable Beta-1.71 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Martin W. MacKay Ph.D. (Age 68)Co-Founder & Executive Chairman Comp: $723.35kDr. Stephen Uden M.B (Age 66)M.D., Co-Founder, President, CEO & Director Comp: $723.35kMr. Jonathan I. Lieber M.B.A. (Age 54)CFO & Treasurer Comp: $667.13kDr. Steven W. Ryder F.A.C.P (Age 72)M.D., Chief Medical Officer Comp: $680.22kKey CompetitorsMagenta TherapeuticsNASDAQ:MGTACytomX TherapeuticsNASDAQ:CTMXInnate PharmaNASDAQ:IPHACaribou BiosciencesNASDAQ:CRBUSkye BioscienceNASDAQ:SKYEView All CompetitorsInstitutional OwnershipAlmitas Capital LLCBought 100,876 shares on 8/16/2024Ownership: 0.243%Point72 Asia Singapore Pte. Ltd.Bought 45,531 shares on 8/15/2024Ownership: 0.110%Hsbc Holdings PLCBought 17,531 shares on 8/12/2024Ownership: 0.042%Johnson & JohnsonBought 3,636,363 shares on 8/9/2024Ownership: 8.773%Renaissance Technologies LLCSold 147,400 shares on 8/9/2024Ownership: 0.822%View All Institutional Transactions RLYB Stock Analysis - Frequently Asked Questions How have RLYB shares performed this year? Rallybio's stock was trading at $2.39 at the start of the year. Since then, RLYB shares have decreased by 54.0% and is now trading at $1.10. View the best growth stocks for 2024 here. How were Rallybio's earnings last quarter? Rallybio Co. (NASDAQ:RLYB) posted its earnings results on Thursday, August, 8th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. The business earned $0.30 million during the quarter. When did Rallybio IPO? Rallybio (RLYB) raised $80 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 5,750,000 shares at a price of $13.00-$15.00 per share. Who are Rallybio's major shareholders? Top institutional investors of Rallybio include Johnson & Johnson (8.77%), Renaissance Technologies LLC (0.82%), Almitas Capital LLC (0.24%) and Acadian Asset Management LLC (0.16%). Insiders that own company stock include Kush Parmar, Jonathan I Lieber, Opportunities I LP 5Am, Martin Mackay, Stephen Uden and Jeffrey M Fryer. View institutional ownership trends. How do I buy shares of Rallybio? Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RLYB) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLYB Stock Alerts